Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + DC vaccine followed by trifluridine/tipiracil + bevacizumab in refractory MSS/pMMR metastatic colorectal cancer
2024-514053-30-00Phase 2Authorised
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, DC-VACCINE IRST-IRCCS, trifluridine + tipiracil and bevacizumab in colorectal cancer (CRC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Overall response rate (ORR) of chemotherapy. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-514053-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514053-30-00.